IN BRIEF: EMA starts rolling review of Covid treatment by GSK and Vir

GlaxoSmithKline PLC - Brentford, Middlesex-based pharmaceutical firm - GSK and Vir Biotechnology ...

Alliance News 7 May, 2021 | 1:08PM
Email Form Facebook Twitter LinkedIn RSS

GlaxoSmithKline PLC - Brentford, Middlesex-based pharmaceutical firm - GSK and Vir Biotechnology Inc say the European Medicines Agency has started a rolling review of test results for their Covid-19 treatment sotrovimab. The review is for use in people 12 years and older. A rolling review means the EMA will evaluate the test data on sotrovimab as it becomes available. A formal marketing authorisation application will be made once there is enough supporting evidence. Sotrovimab has not yet been granted marketing authorisation anywhere in the world, though an Emergency Use Authorization application has been submitted to the US Food & Drug Administration.

Current stock price: 1,350.80 pence

Year-to-date change: up 0.7%

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
GlaxoSmithKline PLC 1,639.50 GBX 0.21

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures